8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Date of Report (Date of earliest event reported): May 9, 2011

MEDCATH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-33009	56-2248952
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

10720 Sikes Place
Charlotte, North Carolina 28277

(Address of principal executive offices, including zip code)

(704) 815-7700

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On May 9, 2011, MedCath Corporation issued a press release announcing its results of operations for the second fiscal quarter ended Mach 31, 2011. A copy of the press release and supplemental financial information are furnished as Exhibits 99.1 and 99.2, respectively.

Item 9.01. Financial Statements and Exhibits

Exhibit 99.1 Press Release dated May 9, 2011

Exhibit 99.2 Supplemental Financial Information

Exhibits 99.1 and 99.2 listed in this Item 9.01 are being furnished under Item 2.02 and shall not be deemed “filed” for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MEDCATH CORPORATION
Date: May 9, 2011	By:	/s/ James A. Parker
		James A. Parker
		Executive Vice President and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No.	Description
Exhibit 99.1	Press Release dated May 9, 2011
Exhibit 99.2	Supplemental Financial Information

EX-99.1

Exhibit 99.1

MEDCATH CONTACT:
O. Edwin French	Art Parker
President/Chief Executive Officer	Chief Financial Officer
(704) 815-7700	(704) 815-7700

MEDCATH CORPORATION REPORTS SECOND FISCAL QUARTER EARNINGS

          CHARLOTTE, N.C., May 9, 2011 — MedCath Corporation (Nasdaq: MDTH), a healthcare provider focused on high acuity healthcare services, today announced operating results for its second fiscal quarter ended March 31, 2011. On April 26, 2011, MedCath announced its intention to release the operating results for its second fiscal quarter ended March 31, 2011 on Tuesday, May 10, 2011. MedCath elected to release its quarterly results today and simultaneously with today’s announcement that it has entered into definitive agreements relating to the sale of Arkansas Heart Hospital and Heart Hospital of New Mexico (MedCath Corporation Announces Entering Into Definitive Agreements Relating to the Sale of Arkansas Heart Hospital and Heart Hospital of New Mexico, May 9, 2011). The operating results of Arkansas Heart Hospital and Heart Hospital of New Mexico are included in the financial results for all periods included in this release.

Second Fiscal Quarter Highlights

• Net revenue of $97.2 million, up 0.4% compared to the second quarter of fiscal 2010.

• Loss from continuing operations of ($12.3) million and adjusted EBITDA of $9.8 million, up 8.2% compared to second quarter of fiscal 2010. Adjusted EBITDA margin up 80 basis points to 10.1% from 9.3%.

• Diluted loss per share from continuing operations of ($0.61) and adjusted EPS of $0.05.

• Total admissions decrease for the second fiscal quarter of 2011 of 0.3%, and adjusted admissions decrease of 0.4%, compared to second quarter of fiscal 2010.

Second Quarter of Fiscal 2011 Results Compared to Second Quarter of Fiscal 2010 Results

              MedCath’s reported net revenue increased 0.4% to $97.2 million in the second quarter of fiscal 2011 compared to $96.8 million in the second quarter of fiscal 2010. Net loss was $(13.5) million in the second quarter of fiscal 2011 compared to $(11.2) million in the second quarter of fiscal 2010. MedCath’s income from continuing operations was $(8.9) million, or $(0.61) per diluted share, in the second quarter of fiscal 2011 compared to $(6.8) million, or $(0.46) per diluted share, in the second quarter of fiscal 2010.

                MedCath’s second quarter of fiscal 2011 financial results include the following items:

• $19.5 million, or ($0.59) per diluted share, in long-lived asset impairment expense related to two hospitals;

• $1.6 million, or ($0.05) per diluted share, of professional fees and other expenses incurred in connection with MedCath’s strategic options process announced on March 1, 2010;

• $0.9 million, or ($0.03) per diluted share, in share-based compensation expense; and

• $0.2 million, or $0.01 per diluted share, related to a gain on the sale of a small unconsolidated affiliate.

          MedCath’s second quarter of fiscal 2010 financial results include the following items:

• $14.7 million, or ($0.60) per diluted share, in impairment expense;

• $1.2 million, or ($0.03) per diluted share, in share-based compensation expense; and

• $1.5 million, or ($0.05) per diluted share, loss on a note receivable.

          Adjusted EBITDA was $9.8 million in the second quarter of fiscal 2011 compared to $9.0 million in the same period of the prior year. MedCath’s Adjusted EPS for the second quarter of fiscal 2011 was $0.05 compared with $0.23 in the second quarter of fiscal 2010.

          Commenting on the quarter, O. Edwin French, MedCath President and Chief Executive Officer, stated “With a smaller number of operating units compared to the prior periods there’s potential for less predictability in this and future quarters. Our operating units were able to mitigate the risk this quarter with good cost management on soft admissions so I’m especially pleased with the earnings accretion we’re reporting.”

Operating Statistics and Cash Flow

          MedCath’s financial results for the second fiscal quarter ended March 31, 2011, reflect a 0.3% decrease in total admissions and a 0.4% decrease in adjusted admissions compared to the second quarter of fiscal 2010. Hospital outpatient cases, including emergency department visits, totaled 15,469 in the second quarter of fiscal 2011, up 14.7% compared to the second quarter of fiscal 2010.

          Total uncompensated care, which includes charity care plus bad debt expense, equaled 13.0% of hospital division net patient revenue before the deduction for charity care in the second quarter of fiscal 2011 compared to 12.5% in the second quarter of fiscal 2010.

          Net cash provided (used) by operating activities from continuing operations for the second quarter of fiscal 2011 was $(6.0) million compared to $9.7 million in the second quarter of fiscal 2010. This decline in net cash provided by operating activities primarily resulted from the payment of taxes during the quarter which were higher than amounts previously paid due to taxable gains incurred on asset sales in prior periods.

Impairment Expense

          MedCath’s second quarter of fiscal 2011 results include a $19.5 million impairment charge related to the reduction in the carrying value of long-lived assets associated with its Hualapai Mountain Medical Center (“HMMC”) and Louisiana Medical Center and Heart Hospital (“LMCHH”). The impairment charge reduced income from continuing operations by $19.5 million and earnings per diluted share by ($0.59) in the second quarter of fiscal 2011. In accordance with generally accepted accounting principles, MedCath evaluates whether or not the carrying values of long lived assets exceed their fair values whenever indications of impairment arise. The fair values of long lived assets were determined by a review of current and anticipated operating performance and outlook, and market-based information. MedCath will continue to evaluate the carrying value of its long lived assets when and if new indications of impairment exist.

          MedCath has intercompany notes outstanding with HMMC and LMCHH as of March 31, 2011. The net realizable value of those notes is the carrying value of the underlying assets that serve as collateral on the notes, which was approximately $44.7 million at March 31, 2011 after taking into consideration the impairment charges.

Use of Non-GAAP Financial Measures

          Included in this press release and the supplemental financial information furnished herewith are certain financial measures that are not calculated and presented in conformity with generally accepted accounting principles (“non-GAAP measures”), such as adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) and adjusted diluted earnings per share from continuing operations (“Adjusted EPS”). The supplemental financial information furnished herewith provides a quantitative reconciliation of Adjusted EBITDA and Adjusted EPS based on the following calculations as and for the periods identified below.

          Adjusted EBITDA for the second fiscal quarter of 2011 represents MedCath’s income (loss) from continuing operations, net of taxes attributable to MedCath’s common stockholders; income tax benefit, net income attributable to noncontrolling interests; equity in net earnings of unconsolidated affiliates; interest and other income; gain on sale of unconsolidated affiliates, interest expense; loss on disposal of property, equipment and other assets; impairment on long-lived assets; depreciation; share-based compensation expense, and professional fees associated with MedCath’s exploration of strategic options. Adjusted EPS for the second fiscal quarter of fiscal 2011 represents MedCath’s diluted loss per share from continuing operations adjusted for gain on sale of unconsolidated affiliates, professional fees associated with MedCath’s consideration of strategic options; impairment on long-lived assets and share-based compensation expense.

          Adjusted EBITDA for the first six months of fiscal quarter of 2011 represents MedCath’s income (loss) from continuing operations, net of taxes attributable to MedCath’s common stockholders; income tax benefit, net income attributable to noncontrolling interests; equity in net earnings of unconsolidated affiliates; interest and other income; gain on sale of unconsolidated affiliates, interest expense; loss on disposal of property, equipment and other assets; impairment on long-lived assets; depreciation; share-based compensation expense; sales tax refunds, and professional fees associated with MedCath’s exploration of strategic options. Adjusted EPS for the first six months of fiscal quarter of fiscal 2011 represents MedCath’s diluted loss per share from continuing operations adjusted for gain on sale of unconsolidated affiliates, professional fees associated with MedCath’s consideration of strategic options; impairment on long-lived assets; sales tax refunds, and share-based compensation expense.

          Adjusted EBITDA for the second fiscal quarter of 2010 represents MedCath’s income (loss) from continuing operations, net of taxes attributable to MedCath’s

common stockholders, income tax benefit; net income attributable to noncontrolling interests; equity in earnings of unconsolidated affiliates; interest and other income, net; interest expense; loss on disposal of property, equipment and other assets; depreciation; share-based compensation expense, impairment on long-lived assets, and loss on note receivable. Adjusted EPS for the second fiscal quarter of fiscal 2010 represents MedCath’s diluted loss per share from continuing operations adjusted for share-based compensation expense; impairment loss on long-lived assets, and loss on note receivable.

          Adjusted EBITDA for the first six months of fiscal quarter of 2010 represents MedCath’s income (loss) from continuing operations, net of taxes attributable to MedCath’s common stockholders, income tax benefit; net income attributable to noncontrolling interests; equity in earnings of unconsolidated affiliates; interest and other income, net; interest expense; loss on disposal of property, equipment and other assets; depreciation; share-based compensation expense, impairment on long-lived assets; pre-opening expense, and loss on note receivable. Adjusted EPS for the first six months of fiscal quarter of fiscal 2010 represents MedCath’s diluted loss per share from continuing operations adjusted for share-based compensation expense; impairment loss on long-lived assets; pre-opening expense, and loss on note receivable.

          MedCath’s management uses Adjusted EBITDA to measure the performance of MedCath’s various operating entities, to compare actual results to historical and budgeted results and to make capital allocation decisions. Management provides Adjusted EBITDA and Adjusted EPS to investors to assist them in performing their analyses of MedCath’s historical operating results. Further, management believes that many investors in MedCath also invest in, or have knowledge of, other healthcare companies that use Adjusted EBITDA and/or Adjusted EPS as a financial performance measure. Because Adjusted EBITDA and Adjusted EPS are non-GAAP measures, Adjusted EBITDA and Adjusted EPS, as defined above, may not be comparable to other similarly titled measures of other companies. MedCath has included a supplemental schedule with the financial statements that accompanies this press release that reconciles historical Adjusted EBITDA to MedCath’s income from continuing operations attributable to MedCath’s common stockholders and Adjusted EPS to diluted EPS from continuing operations.

          This press release and the financial information included therewith will be accessible on the web, by going to www.medcath.com, “Investor Relations,” then clicking on “News.”

          MedCath Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused on high acuity services with the diagnosis and treatment of cardiovascular disease being a primary service offering. MedCath owns an interest in and operates six hospitals with a total of 533 licensed beds, located in Arizona, Arkansas, California, Louisiana, New Mexico, and Texas.

# # #

          Parts of this announcement contain forward-looking statements that involve risks and uncertainties, including statements regarding the evaluation of long lived assets and possible new indications of impairment. Although management believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic, regulatory and competitive uncertainties and contingencies that are difficult or impossible to predict accurately and are beyond our control including, but not limited to, the implementation of healthcare reform legislation and future enactment of changes in federal law that would further limit physician hospital ownership. Actual results could differ materially from those projected in these forward-looking statements. We do not assume any obligation to update these statements in a news release or otherwise should material facts or circumstances change in ways that would affect their accuracy. The preparation of MedCath’s second quarter of fiscal 2011 operating results required management to make estimates and assumptions that affect reported amounts of revenues and expenses. There is a reasonable possibility that actual results may vary significantly from those estimates.

          These various risks and uncertainties are described in detail in “Risk Factors” in MedCath’s Annual Report or Form 10-K for the year ended September 30, 2010 filed with the Securities and Exchange Commission on December 14, 2010. Copies of our filings with the Securities and Exchange Commission, including exhibits, are available at www.sec.gov to review.

EX-99.2

Exhibit 99.2

MEDCATH CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

	Three Months Ended March 31,						Six Months Ended March 31,
	2011			2010			2011			2010
Net revenue	$	97,163		$	96,777		$	186,063		$	184,607
Operating expenses:
Personnel expense		33,859			33,150			66,313			64,786
Medical supplies expense		23,189			23,581			42,411			45,688
Bad debt expense		10,006			9,931			19,715			17,437
Other operating expenses		22,843			22,296			46,959			44,640
Pre-opening expenses		—			—			—			866
Depreciation		4,630			6,124			9,517			12,064
Impairment of long-lived assets		19,548			14,700			19,548			14,700
Loss (gain) on disposal of property, equipment and other assets		178			(69	)		271			27
Total operating expenses		114,253			109,713			204,734			200,208
Loss from operations		(17,090	)		(12,936	)		(18,671	)		(15,601	)
Other income (expenses):
Interest expense		(997	)		(1,054	)		(2,079	)		(1,999	)
Interest and other income		50			15			539			85
Gain on sale of unconsolidated affiliates		179			—			15,570			—
Loss on note receivable		—			(1,507	)		—			(1,507	)
Equity in net earnings of unconsolidated affiliates		1,258			3,092			1,860			4,608
Total other income (expense), net		490			546			15,890			1,187
Loss from continuing operations before income taxes		(16,600	)		(12,390	)		(2,781	)		(14,414	)
Income tax benefit		(7,695	)		(5,639	)		(3,213	)		(6,976	)
(Loss) income from continuing operations		(8,905	)		(6,751	)		432			(7,438	)
(Loss) income from discontinued operations, net of taxes		(1,401	)		(1,934	)		37,727			(3,064	)
Net (loss) income		(10,306	)		(8,685	)		38,159			(10,502	)
Less: Net income attributable to noncontrolling interest		(3,189	)		(2,524	)		(14,615	)		(3,364	)
Net (loss) income attributable to MedCath Corporation	$	(13,495	)	$	(11,209	)	$	23,544		$	(13,866	)
Amounts attributable to MedCath Corporation common stockholders:
Loss from continuing operations, net of taxes	$	(12,341	)	$	(8,970	)	$	(5,179	)	$	(10,872	)
(Loss) income from discontinued operations, net of taxes		(1,154	)		(2,239	)		28,723			(2,994	)
Net (loss) income	$	(13,495	)	$	(11,209	)	$	23,544		$	(13,866	)
(Loss) earnings per share, basic
Loss from continuing operations attributable to MedCath Corporation common stockholders	$	(0.61	)	$	(0.46	)	$	(0.26	)	$	(0.55	)
(Loss) income from discontinued operations attributable to MedCath Corporation common stockholders		(0.06	)		(0.11	)		1.43			(0.15	)
(Loss) earnings per share, basic	$	(0.67	)	$	(0.57	)	$	1.17		$	(0.70	)
(Loss) earnings per share, diluted
Loss from continuing operations attributable to MedCath Corporation common stockholders	$	(0.61	)	$	(0.46	)	$	(0.26	)	$	(0.55	)
(Loss) income from discontinued operations attributable to MedCath Corporation common stockholders		(0.06	)		(0.11	)		1.43			(0.15	)
(Loss) earnings per share, diluted	$	(0.67	)	$	(0.57	)	$	1.17		$	(0.70	)
Weighted average number of shares, basic		20,208			19,829			20,075			19,786
Dilutive effect of stock options and restricted stock		—			—			6			—
Weighted average number of shares, diluted		20,208			19,829			20,081			19,786

MEDCATH CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)

	March 31,			September 30,
	2011			2010
	(Unaudited)
Current assets:
Cash and cash equivalents	$	119,735		$	33,141
Accounts receivable, net		49,748			43,811
Income tax receivable		—			6,188
Medical supplies		10,373			10,550
Deferred income tax assets		8,500			13,247
Prepaid expenses and other current assets		12,949			13,453
Current assets of discontinued operations		46,619			47,920
Total current assets		247,924			168,310
Property and equipment, net		153,469			182,222
Other assets		18,484			24,716
Non-current assets of discontinued operations		1,152			119,290
Total assets	$	421,029		$	494,538
Current liabilities:
Accounts payable	$	16,633		$	15,716
Income tax payable		3,205			—
Accrued compensation and benefits		14,775			16,418
Other accrued liabilities		15,503			16,663
Current portion of long-term debt and obligations under capital leases		32,793			16,672
Current liabilities of discontinued operations		14,174			35,044
Total current liabilities		97,083			100,513
Long-term debt		—			52,500
Obligations under capital leases		5,191			6,500
Other long-term obligations		2,804			5,053
Long-term liabilities of discontinued operations		—			35,968
Total liabilities		105,078			200,534
Commitments and contingencies
Redeemable noncontrolling interest		7,356			11,534
Stockholders’ equity:
Preferred stock, $0.01 par value, 10,000,000 shares authorized; none issued		—			—
Common stock, $0.01 par value, 50,000,000 shares authorized; 22,281,828 issued and 20,327,467 outstanding at March 31, 2011; 22,423,666 issued and 20,469,305 outstanding at September 30, 2010		216			216
Paid-in capital		458,573			457,725
Accumulated deficit		(116,247	)		(139,791	)
Accumulated other comprehensive loss		—			(444	)
Treasury stock, at cost;
1,954,361 shares at March 31, 2011 and September 30, 2010		(44,797	)		(44,797	)
Total MedCath Corporation stockholders’ equity		297,745			272,909
Noncontrolling interest		10,850			9,561
Total equity		308,595			282,470
Total liabilities and equity	$	421,029		$	494,538

MEDCATH CORPORATION
SELECTED OPERATING DATA
(In thousands, except per share data and selected operating data)
(Unaudited)

	Three Months Ended March 31,									Six Months Ended March 31,
	2011			2010			% Change			2011			2010			% Change
Statement of Operations Data:
Net revenue	$	97,163		$	96,777			0.4	%	$	186,063		$	184,607			0.8	%
Adjusted EBITDA (1)	$	9,770		$	9,033			8.2	%	$	15,575		$	13,882			12.2	%
Loss from operations	$	(17,090	)	$	(12,936	)		32.1	%	$	(18,671	)	$	(15,601	)		19.7	%
Loss from continuing operations, net of taxes	$	(12,341	)	$	(8,970	)		37.6	%	$	(5,179	)	$	(10,872	)		(52.4	)%
Loss per share from continuing operations, basic	$	(0.61	)	$	(0.46	)		32.1	%	$	(0.26	)	$	(0.55	)		(53.0	)%
Loss per share from continuing operations, diluted	$	(0.61	)	$	(0.46	)		32.1	%	$	(0.26	)	$	(0.55	)		(53.1	)%

(1) See Supplemental Financial Disclosure-Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.

	Three Months Ended March 31,									Six Months Ended March 31,
	2011			2010			% Change			2011			2010			% Change
Selected Operating Data (a):
Number of hospitals		5			5						5			5
Licensed beds (c)		421			421						421			421
Staffed and available beds (d)		380			380						380			380
Admissions (e)		4,905			4,918			(0.3	)%		9,343			9,404			(0.6	)%
Adjusted admissions (f)		7,231			7,257			(0.4	)%		14,074			13,745			2.4	%
Patient days (g)		18,840			18,690			0.8	%		35,085			35,362			(0.8	)%
Adjusted patient days (h)		28,018			27,626			1.4	%		53,194			51,905			2.5	%
Average length of stay (days) (i)		3.84			3.80			1.1	%		3.76			3.76			0.0	%
Occupancy (j)		55.1	%		54.6	%					50.7	%		51.1	%
Inpatient catheterization procedures (k)		1,940			2,054			(5.6	)%		3,732			3,888			(4.0	)%
Inpatient surgical procedures (l)		1,187			1,171			1.4	%		2,219			2,259			(1.8	)%
Hospital net revenue	$	94,996		$	93,881			1.2	%	$	181,614		$	178,263			1.9	%
Combined Operating Data (b):
Number of hospitals		6			6						6			6
Licensed beds (c)		533			533						533			533
Staffed and available beds (d)		489			488						489			488
Admissions (e)		6,658			6,933			(4.0	)%		12,914			13,136			(1.7	)%
Adjusted admissions (f)		10,441			10,953			(4.7	)%		20,608			20,622			(0.1	)%
Patient days (g)		24,514			24,883			(1.5	)%		46,233			46,710			(1.0	)%
Adjusted patient days (h)		38,409			38,985			(1.5	)%		73,593			72,817			1.1	%
Average length of stay (days) (i)		3.68			3.59			2.5	%		3.58			3.56			0.6	%
Occupancy (j)		55.7	%		56.7	%					51.9	%		52.6	%
Inpatient catheterization procedures (k)		2,129			2,286			(6.9	)%		4,101			4,318			(5.0	)%
Inpatient surgical procedures (l)		1,603			1,553			3.2	%		3,054			3,002			1.7	%
Hospital net revenue	$	122,606		$	119,333			2.7	%	$	235,325		$	227,980			3.2	%

(a)	Selected operating data includes consolidated hospitals in operation as of the end of the period reported in continuing operations but does not include hospitals which are accounted for using the equity method or as discontinued operations in our consolidated financial statements.
(b)	Combined operating data includes hospitals in operation as of the end of the period reported in continuing operations including hospitals which are accounted for using the equity method in our consolidated financial statements.
(c)	Licensed beds represent the number of beds for which the appropriate state agency licenses a facility regardless of whether the beds are actually available for patient use.
(d)	Staffed and available beds represent the number of beds that are readily available for patient use at the end of the period.
(e)	Admissions represent the number of patients admitted for inpatient treatment.
(f)	Adjusted admissions is a general measure of combined inpatient and outpatient volume. We computed adjusted admissions by dividing gross patient revenue by gross inpatient revenue and then multiplying the quotient by admissions.
(g)	Patient days represent the total number of days of care provided to inpatients.
(h)	Adjusted patient days is a general measure of combined inpatient and outpatient volume. We computed adjusted patient days by dividing gross patient revenue by gross inpatient revenue and then multiplying the quotient by patient days.
(i)	Average length of stay (days) represents the average number of days inpatients stay in our hospitals.
(j)	We computed occupancy by dividing patient days by the number of days in the period and then dividing the quotient by the number of staffed and available beds.
(k)	Inpatients with a catheterization procedure represent the number of inpatients with a procedure performed in one of the hospitals’ catheterization labs during the period.
(l)	Inpatient surgical procedures represent the number of surgical procedures performed on inpatients during the period.

MEDCATH CORPORATION
SUPPLEMENTAL FINANCIAL DISCLOSURE — RECONCILIATION OF GAAP FINANCIAL MEASURES
TO NON-GAAP FINANCIAL MEASURES
(Unaudited)

The following table reconciles the loss from continuing operations, net of taxes attributable to MedCath Corporation’s common stockholders as derived directly from MedCath Corporation’s consolidated financial statements to Adjusted EBITDA for the three and six months ended March 31, 2011 and 2010.

	Three Months Ended March 31,						Six Months Ended March 31,
	2011			2010			2011			2010
	(in thousands)						(in thousands)
Loss from continuing operations, net of taxes	$	(12,341	)	$	(8,970	)	$	(5,179	)	$	(10,872	)
Add:
Income tax (benefit) expense		(7,695	)		(5,639	)		(3,213	)		(6,976	)
Net income attributable to noncontrolling interest		3,436			2,216			5,610			3,434
Equity in net earnings of unconsolidated affiliates		(1,258	)		(3,092	)		(1,860	)		(4,608	)
Interest and other income		(50	)		(15	)		(539	)		(85	)
Loss on note receivable		—			1,507			—			1,507
Gain on sale of unconsolidated affiliates		(179	)		—			(15,570	)		—
Interest expense		997			1,054			2,079			1,999
Loss (gain) on disposal of property, equipment and other assets		178			(69	)		271			27
Impairment of long-lived assets		19,548			14,700			19,548			14,700
Depreciation		4,630			6,124			9,517			12,064
Pre-opening expenses		—			—			—			866
Share-based compensation expense		922			1,217			2,854			1,826
Professional fees for strategic options process		1,582			—			4,144			—
Sales tax refunds, net		—			—			(2,087	)		—
Adjusted EBITDA	$	9,770		$	9,033		$	15,575		$	13,882

The following table reconciles MedCath Corporation’s diluted (loss) earnings per share from continuing operations, net of taxes attributable to MedCath Corporation’s common stockholders as derived directly from MedCath’s consolidated financial statements to Adjusted diluted earnings per share from continuing operations (inclusive of the effect of dilutive shares) for the three and six months ended March 31, 2011 and 2010.

	Three Months Ended March 31,						Six Months Ended March 31,
	2011			2010			2011			2010
Diluted (loss) earnings per share	$	(0.61	)	$	(0.46	)	$	(0.26	)	$	(0.55	)
Add:
Gain on sale of unconsolidated affiliates		(0.01	)		—			(0.47	)		—
Professional fees for strategic options process		0.05			—			0.13			—
Sales tax refunds		—			—			(0.06	)		—
Impairment of long-lived assets		0.59			0.60			0.59			0.60
Loss on note receivable		—			0.05			—			0.05
Share-based compensation expense		0.03			0.04			0.09			0.06
Pre-opening expense		—			—			—			0.02
Adjusted diluted earnings per share	$	0.05		$	0.23		$	0.02		$	0.18